| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology |
1 Division of Neuroscience, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon; Departments of 2 Pathology and 3 Behavioral Neuroscience, Oregon Health and Science University, Portland, Oregon; and 4 Department of Dermatology, University of California, Davis, California
Requests for reprints: Eliot Spindel, Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR 97006. Phone: 503-690-5512; Fax: 503-690-5384; E-mail: spindele{at}ohsu.edu.
The importance of acetylcholine as a neurotransmitter in the nervous system is well established, but little is yet known about its recently described role as an autocrine and paracrine hormone in a wide variety of nonneuronal cells. Consistent with the expression of acetylcholine in normal lung, small cell lung carcinoma (SCLC) synthesize and secrete acetylcholine, which acts as an autocrine growth factor through both nicotinic and muscarinic cholinergic mechanisms. The purpose of this study was to determine if interruption of autocrine muscarinic cholinergic signaling has potential to inhibit SCLC growth. Muscarinic receptor (mAChR) agonists caused concentration-dependent increases in intracellular calcium and mitogen-activated protein kinase (MAPK) and Akt phosphorylation in SCLC cell lines. The inhibitory potency of mAChR subtypeselective antagonists and small interfering RNAs (siRNAs) on acetylcholine-increased intracellular calcium and MAPK and Akt phosphorylation was consistent with mediation by M3 mAChR (M3R). Consistent with autocrine acetylcholine secretion stimulating MAPK and Akt phosphorylation, M3R antagonists and M3R siRNAs alone also caused a decrease in basal levels of MAPK and Akt phosphorylation in SCLC cell lines. Treatment of SCLC cells with M3R antagonists inhibited cell growth both in vitro and in vivo and also decreased MAPK phosphorylation in tumors in nude mice in vivo. Immunohistochemical staining of SCLC and additional cancer types showed frequent coexpression of acetylcholine and M3R. These findings suggest that M3R antagonists may be useful adjuvants for treatment of SCLC and, potentially, other cancers. [Cancer Res 2007;67(8):393644]
This article has been cited by other articles:
![]() |
K. Cheng, R. Samimi, G. Xie, J. Shant, C. Drachenberg, M. Wade, R. J. Davis, G. Nomikos, and J.-P. Raufman Acetylcholine release by human colon cancer cells mediates autocrine stimulation of cell proliferation Am J Physiol Gastrointest Liver Physiol, September 1, 2008; 295(3): G591 - G597. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Song, H. S. Sekhon, X. W. Fu, M. Maier, Y. Jia, J. Duan, B. J. Proskosil, C. Gravett, J. Lindstrom, G. P. Mark, et al. Activated Cholinergic Signaling Provides a Target in Squamous Cell Lung Carcinoma Cancer Res., June 15, 2008; 68(12): 4693 - 4700. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |